Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) for nadunolimab in first-line NSCLC and pancreatic ductal adenocarcinoma (PDAC) support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy, with new encouraging clinical/biomarker data for PDAC reported in September 2023. The company is preparing for a Phase IIb trial in PDAC patients. Further, in October 2023, Cantargia announced positive interim efficacy and safety data from TRIFOUR (Phase Ib/II), assessing nadunolimab in triple-negative breast cancer. Additionally, Cantargia recently announced a $1.1m grant, which will support a new Phase Ib/IIa clinical trial for nadunolimab in leukaemia. A second programme, CAN10, is being developed for the treatment of autoimmune diseases; the company initiated a Phase I trial in September 2023. At end-Q223, Cantargia had a cash and short-term investment position of SEK287.1m.